Trial of Screening for ALOA-IgG AtheroAbzyme Test

Phase 3

Completed

• Conditions: Myocardial Ischemia; Acute Coronary Syndrome
• Interventions: Device: ALOA IgG-Elisa; Device: ALOA IgG-AtheroAbzyme

• Registration Number: NCT01272986
• Lead Sponsor: Omicron Pharmaceuticals

Brief Summary

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01
• Study First Submitted: 2011-01-07
• Study First Submitted QC: 2011-01-07
• Study First Posted: 2011-01-10
• Status Verified: 2011-03
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Last Update Submitted: 2011-03-06
• Last Update Posted: 2011-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Healthy patients
• High Risk patients or Asymptomatic myocardial Ischemic patients
• Acute Coronary Syndrome patients

Exclusion Criteria

• None

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy patients	ALOA IgG-Elisa	-
Healthy patients	ALOA IgG-AtheroAbzyme	-
Asymptomatic myocardial Ischemic patients	ALOA IgG-Elisa	-
Asymptomatic myocardial Ischemic patients	ALOA IgG-AtheroAbzyme	-
Acute Coronary Syndrome Patients	ALOA IgG-Elisa	-
Acute Coronary Syndrome Patients	ALOA IgG-AtheroAbzyme	-

Primary Outcome Measures

Name	Time	Method
Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients	Three months

Trial Locations

Locations (1)

Bahman Hospital; 🇱🇧 Beirut, Haret Hriek, Lebanon